Steven H. Stein, Chief Medical Officer and Head of Late-Stage Development at Incyte Corp, filed a Form 4 on November 18, 2026, disclosing an option exercise and same-day sale of 576 shares of common stock on November 16, 2026.

Key Highlights

  • Option exercise: Stein acquired 576 shares of Incyte common stock via an employee stock option exercise (transaction code M) at an exercise price of $68.25 per share on November 16, 2026.
  • Same-day sale: Stein disposed of 576 shares (transaction code S) at $121.98 per share on November 16, 2026, pursuant to a Rule 10b5-1(c) plan.
  • Post-transaction ownership: Following the transactions, Stein directly held 30,916 shares of common stock.
  • Unvested units included: According to the filing, 29,338 of those shares represent common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.
  • Remaining options: Stein beneficially owned 20,146 employee stock options following the reported transaction, with an exercise price of $68.25 and an expiration date of July 14, 2035.
  • Rule 10b5-1 plan: The filing indicates the sale was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Stein's Option Exercise and Share Sale at Incyte Corp

According to the Form 4 filed with the SEC, Steven H. Stein, who serves as CMO and Head of Late-Stage Development at Incyte Corp (NASDAQ:INCY), reported two transactions dated November 16, 2026. First, he exercised 576 employee stock options at an exercise price of $68.25 per share, acquiring 576 shares of common stock. Immediately thereafter, he sold those same 576 shares at $121.98 per share. The filing notes the sale was conducted under a written plan meeting the conditions of Rule 10b5-1(c).

The filing reports that after both transactions, Stein directly held 30,916 shares of Incyte common stock. The filing clarifies that 29,338 of those shares are issuable under previously reported restricted stock units and earned performance stock units that remain unvested, meaning direct unrestricted holdings are a subset of the total reported figure.

In Table II, the filing discloses that Stein retains 20,146 employee stock options with an exercise price of $68.25 and an expiration date of July 14, 2035. The filing states those options, originally granted July 15, 2025, "become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years." The Form 4 was signed by Elizabeth Feeney as Attorney-In-Fact on November 18, 2026.

What Was Disclosed

Incyte Corp officer Steven H. Stein disclosed a Rule 10b5-1 plan exercise and sale of 576 shares on November 16, 2026, leaving him with a reported direct beneficial ownership of 30,916 shares and 20,146 remaining employee stock options.